Increase in Streptococcus pneumoniae serotype 3 associated parapneumonic pleural effusion/empyema after the introduction of PCV13 in Germany

IntroductionPediatric pneumococcal pneumonia complicated by parapneumonic pleural effusion/empyema (PPE/PE) remains a major concern despite general immunization with pneumococcal conjugate vaccines (PCVs).MethodsIn a nationwide pediatric hospital surveillance study in Germany we identified 584 children <18 years of age with bacteriologically confirmed PPE/PE from October 2010 to June 2018. Streptococcus pneumoniae was identified by culture and/or PCR of blood samples and/or pleural fluid and serotyped.ResultsS. pneumoniae was identified in 256 of 584 (43.8%) children by culture (n = 122) and/or PCR (n = 207). The following pneumococcal serotypes were detected in 114 children: serotype 3 (42.1%), 1 (25.4%), 7F (12.3%), 19A (7.9%), other PCV13 serotypes (4.4%) and non-PCV13 serotypes (7.9%). Between October 2010 and June 2014 serotype 1 (38.1%) and serotype 3 (25.4%) were most prevalent, whereas between July 2014 and June 2018 serotype 3 (62.7%) and non-PCV13 serotypes (15.7%) were dominant. Compared to children with other pneumococcal serotypes, children with serotype 3 associated PPE/PE were younger (median 3.2 years [IQR 2.1–4.3 years] vs. median 5.6 years [IQR 3.8–8.2 years]; p < 0.001) and more frequently admitted to intensive care (43 [89.6%] vs. 48 [73.8%]; p = 0.04). Seventy-six of 114 (66.7%) children with pneumococcal PPE/PE had been vaccinated with pneumococcal vaccines. Thirty-nine of 76 (51.3%) had received a vaccine covering the serotype detected. Thirty of these 39 breakthrough cases were age-appropriately vaccinated with PCV13 and considered vaccine failures, including 26 children with serotype 3, three children with serotype 19A and one child with serotype 1.ConclusionFollowing the introduction of PCV13 in general childhood vaccination we observed a strong emergence of serotype 3 associated PPE/PE in the German pediatric population, including a considerable number of younger children with serotype 3 vaccine breakthrough cases and failures. Future PCVs should not only cover newly emerging serotypes, but also include a more effective component against serotype 3.     

Correlation between cow’s milk protein allergy and otitis media: a systematic review

ObjectivesTo review the evidence pertaining to the association between cow’s milk protein allergy and recurrent acute otitis media and otitis media with effusion.MethodsThe CENTRAL, Web of Science, EMBASE, MEDLINE, LILACS databases, and gray literature were searched.ResultsFour studies were included, identifying the prevalence rates: 0.2% of delayed speech due to chronic otitis media with effusion in 382 children with cow’s milk protein allergy, 10.7% of cow’s milk protein allergy in 242 children who underwent ENT procedures, 40% of cow’s milk protein allergy in 25 children with recurrent otitis media with effusion and higher tendency to otitis media in children with cow’s milk protein allergy of 186 children (1.5 + 0.6 vs. 0.4 + 0.1; p < 0.1).ConclusionConsidering the characteristics and methodological variations of the identified studies, it is not possible to state that there is reliable evidence of an association between cow’s milk protein allergy and otitis media.     

小儿心包积液28例临床分析

目的：探讨小儿心包积液的病因、分类及诊断。方法：病例回顾性分析。结果：28例中，化脓性心包积液4例，结缔组织疾病所致心包积液16例，肾病综合征所致心包答液4例，病毒性、肺吸虫性、幼年型粘液性水肿及肿瘤性心包积液各1例。治愈、好转25例，另3例，分别死于急性心包填塞，风湿性全心炎、心功能不全、呼衰、纵隔肿瘤广泛转移。结论：小儿心包积液，可由多种致病因素引起。其临床特点，对该病的诊治有重要意义。     

含补金片方案治疗结核性渗出性胸膜炎疗效观察

目的：探讨结核性渗出性胸膜炎的治疗方法。方法：96例初治结核性胸膜炎患者随机分为2组,对照组应用普通化疗方案2HRZE（S）/4HR;治疗组在对照组基础上,强化期加用补金片治疗。观察6个月,分析两组疗效。结果：治疗2周、4周及8周末胸水吸收总有效率治疗组为83.33%、91.67%和95.83%;对照组为64.58%、72.92%和79.17%,治疗6个月胸膜肥厚与粘连发生率治疗组为14.58%,对照组为41.67%,两组比较均有显著性差异（P〈0.05）。结论：补金片可促进胸液吸收,加快临床症状消失,防止胸膜肥厚粘连,以及防止肝损害等,值得临床推广。     

超声引导穿刺置入微导管法治疗恶性心包积液的评价

目的探讨超声引导下穿刺置入微导管法在恶性心包积液治疗中的价值.方法13例恶性心包积液在超声引导下进行心包穿刺,置入硬膜外麻醉导管（微导管）,通过导管抽出心包积液并注入化疗药物.结果13例均成功穿刺并顺利置入微导管,引流积液400～780 ml,平均530 ml.治疗后3、12、24个月存活率分别为92%（12/13）,78%（7/9）和60%（3/5）,无心包积液复发.结论超声引导穿刺置入微导管法治疗恶性心包积液安全、微创、有效、可行.